Tadalafil · Adcirca

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Pulmonary Arterial Hypertension

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
JP
  • Pulmonary arterial hypertension (Adcirca Tablets 20 mg; approved to Eli Lilly Japan, succeeded by Nippon Shinyaku on 2020-04-02)
Product first approved 2009PMDA
EU
  • Pulmonary arterial hypertension, WHO functional class II and III (adults; children from 2 years)
Product first approved 2008EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (48)
Pulmonary Arterial Hypertension
NCT01178073 · GlaxoSmithKline
2010-10-01 – 2014-07-31 · Hypertension, Pulmonary
What this study did
NCT00125918 · Eli Lilly and Company
2005-08 – 2007-08 · Pulmonary Hypertension
What this study did
Other / comorbidity
NCT05179876 · Actelion
2022-05-04 – 2033-09-28 · Hypertension, Pulmonary
What this study did
NCT05844462 · Assistance Publique - Hôpitaux de Paris
2024-02-01 – 2027-12 · Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
What this study did
NCT05206955 · Mayo Clinic
2022-09-16 – 2026-11 · Fontan Palliation
What this study did
NCT06805513 · Sanofi
2025-01-30 – 2026-04-02 · Erectile Dysfunction
What this study did
NCT06520839 · University Medical Centre Ljubljana
2024-05-17 – 2024-12 · Erectile Dysfunction With Diabetes Mellitus
What this study did
NCT06466369 · Al-Azhar University
2024-03-15 – 2024-08-01 · BPH With Other Lower Urinary Tract Symptoms
What this study did
NCT05487755 · Tanta University
2022-02-01 – 2023-09-01 · Diabetic Nephropathy Type 2
What this study did
NCT04984993 · Futura Medical Developments Ltd.
2021-09-14 – 2022-07-13 · Erectile Dysfunction
What this study did
NCT03049540 · Insel Gruppe AG, University Hospital Bern
2017-10-25 – 2021-10-28 · Heart Defects, Congenital, Transposition of Great Vessels With Ventricular Inversion
What this study did
NCT04433559 · Lidia Larrañaga
2020-08 – 2021-08 · Sexual Dysfunctions, Psychological
What this study did
NCT03905018 · Centro Universitario de Ciencias de la Salud, Mexico
2019-05-01 – 2019-09-01 · Obesity and Erectile Dysfuntion
What this study did
NCT01960153 · Massachusetts General Hospital
2013-10 – 2018-05 · Heart Failure, Pulmonary Hypertension
What this study did
NCT02862483 · IlDong Pharmaceutical Co Ltd
2016-03 – 2017-03 · Benign Prostatic Hyperplasia, Erectile Dysfunction
What this study did
NCT01865084 · Eli Lilly and Company
2013-09 – 2016-03 · Muscular Dystrophy, Duchenne
What this study did
NCT01937871 · Eli Lilly and Company
2013-09 – 2015-12 · Benign Prostate Hyperplasia, Erectile Dysfunction
What this study did
NCT00931528 · Radiation Therapy Oncology Group
2009-11 – 2014-11 · Prostate Cancer, Sexual Dysfunction
What this study did
NCT01553981 · Sanjay Gandhi Postgraduate Institute of Medical Sciences
2012-03 – 2014-05 · Lung Diseases, Interstitial
What this study did
NCT01910389 · Carelon Research
2013-11 – 2014-02 · Heart Failure, Pulmonary Hypertension
What this study did
NCT01444651 · Thomas J. Wang, MD
2011-08 – 2013-03 · Cardiovascular Disease, Insulin Resistance, Glucose Intolerance, Obesity
What this study did
NCT01460342 · Eli Lilly and Company
2011-12 – 2012-10 · Benign Prostatic Hyperplasia
What this study did
NCT01152190 · Eli Lilly and Company
2010-09 – 2012-07 · Benign Prostatic Hyperplasia
What this study did
NCT01139762 · Eli Lilly and Company
2010-09 – 2012-05 · Benign Prostatic Hyperplasia, Enlarged Prostate
What this study did
NCT00970632 · Eli Lilly and Company
2009-10 – 2011-01 · Benign Prostatic Hyperplasia (BPH)
What this study did
NCT00855582 · Eli Lilly and Company
2009-03 – 2010-07 · Erectile Dysfunction, Benign Prostatic Hyperplasia
What this study did
NCT00861757 · Eli Lilly and Company
2009-03 – 2010-06 · Benign Prostatic Hyperplasia
What this study did
NCT01117298 · Sanjay Gandhi Postgraduate Institute of Medical Sciences
2009-11 – 2010-05 · Raynaud's Phenomenon, Digital Ulcers, Scleroderma
What this study did
NCT00836693 · Eli Lilly and Company
2009-01 – 2010-01 · Erectile Dysfunction
What this study did
NCT00848081 · Eli Lilly and Company
2009-03 – 2009-12 · Benign Prostatic Hyperplasia
What this study did
NCT00827242 · Eli Lilly and Company
2009-01 – 2009-11 · Benign Prostatic Hyperplasia
What this study did
NCT00734604 · Eli Lilly and Company
2008-08 – 2009-09 · Erectile Dysfunction
What this study did
NCT00626665 · Sanjay Gandhi Postgraduate Institute of Medical Sciences
2007-12 – 2008-04 · Raynaud Disease
What this study did
NCT00422734 · Eli Lilly and Company
2006-11 – 2008-01 · Impotence
What this study did
NCT00381732 · Eli Lilly and Company
2003-10 – 2006-06 · Erectile Dysfunction
What this study did
NCT00215631 · Erasmus Medical Center
2005-10 – 2005-11 · Prostate Cancer, Erectile Dysfunction
What this study did
NCT00421083 · Eli Lilly and Company
2004-09 – 2005-06 · Erectile Dysfunction, Spinal Cord Injuries
What this study did
NCT00547183 · Eli Lilly and Company
2004-10 – 2005-05 · Impotence
What this study did
NCT00122499 · Erasmus Medical Center
2003-02 – 2005-02 · Prostate Cancer, Erectile Dysfunction
What this study did
NCT00547495 · Eli Lilly and Company
2004-03 – 2004-11 · Impotence
What this study did
NCT00547287 · Eli Lilly and Company
2002-11 – 2004-05 · Impotence
What this study did
NCT00547417 · Eli Lilly and Company
2003-07 – 2004-03 · Impotence
What this study did
NCT00547573 · Eli Lilly and Company
2003-04 – 2003-12 · Impotence
What this study did
NCT00547508 · Eli Lilly and Company
2002-10 – 2003-09 · Impotence
What this study did
Phase 2/3 (8)
Other / comorbidity
NCT06583590 · Aswan University Hospital
2024-08-01 – 2025-12-01 · Erectile Dysfunction With Diabetes Mellitus
What this study did
NCT05195775 · University of Florida
2021-12-14 – 2025-09-08 · Duchenne Muscular Dystrophy
What this study did
NCT05955001 · Mansoura University
2023-04-01 – 2025-07 · Erectile Dysfunction, Lower Urinary Tract Symptoms
What this study did
NCT07761806 · Ain Shams University
2024-01-15 – 2024-10-01 · Erectile Dysfunction
What this study did
NCT05971667 · Beni-Suef University
2023-07-30 – 2023-10-30 · IVF
What this study did
NCT05266651 · Kasr El Aini Hospital
2022-03-10 – 2022-05 · Sexual Dysfunction
What this study did
NCT01324999 · University of North Carolina, Chapel Hill
2011-03 – 2013-10 · Pulmonary Hypertension
What this study did
NCT00384930 · Eli Lilly and Company
2006-08 – 2008-10 · Benign Prostatic Hyperplasia
What this study did
Phase 2 (40)
Other / comorbidity
NCT05173896 · Christina Kruuse
2022-05-31 – 2029-12 · Cerebral Small Vessel Diseases, Stroke, Ischemic
What this study did
NCT07576335 · Surgical Outcomes Research Centre (SOuRCe)
2026-08-31 – 2029-11-01 · Erectile Dysfunction Following Radical Prostatectomy, Prostate Cancer, Urinary Incontinence Following Surgical Procedure
What this study did
NCT05937854 · VA Office of Research and Development
2024-04-01 – 2029-03-01 · Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension, Dyspnea
What this study did
NCT07537855 · Northwestern University
2026-09 – 2028-09 · Erectile Dysfunction
What this study did
NCT07172815 · Imperial College London
2025-09 – 2028-08 · Alzheimer Disease
What this study did
NCT07882901 · Los Angeles Brain Science Project
2026-09 – 2027-02-20 · Mild Cognitive Impairment (MCI)
What this study did
NCT06290713 · University of Florida
2024-06-05 – 2026-11 · Duchenne Muscular Dystrophy, Duchenne Disease, Muscular Dystrophy, Muscular Dystrophy in Children, Vasodilation, Exercise, DMD
What this study did
NCT05709574 · University of Arizona
2023-04-20 – 2026-10-30 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT04684589 · Vanderbilt University Medical Center
2021-03-16 – 2025-06-24 · Obesity
What this study did
NCT05014776 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2022-08-22 – 2025-06-19 · Pancreatic Cancer
What this study did
NCT07333976 · Tri-Service General Hospital (TSGH)
2020-01-05 – 2024-08-13 · Prostate Cancer Metastatic Disease, Chemotherapy Induced Peripheral Neuropathy (CIPN), Neurotoxicity
What this study did
NCT03993353 · University of California, San Diego
2020-04-07 – 2024-01-09 · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage III, Head and Neck Cancer Stage IV, Head and Neck Cancer Metastatic, Cancer, Cancer of Esophagus, Cancer, Metastatic, Cancer of Head and Neck, Cancer of Mouth, Cancer of Neck
What this study did
NCT05142254 · Vanderbilt University Medical Center
2022-04-01 – 2023-11-09 · Priapism Due to Sickle Cell Disease
What this study did
NCT03785210 · National Cancer Institute (NCI)
2019-06-05 – 2022-12-31 · Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, Liver Metastasis
What this study did
NCT04069936 · WindMIL Therapeutics
2019-10-15 – 2021-11-30 · Non Small Cell Lung Cancer, Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell, Non Small Cell Lung Cancer Metastatic, NSCLC, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic
What this study did
NCT02611258 · Andrea M. Isidori
2016-07 – 2021-06 · Cushing's Syndrome Cardiomyopathy
What this study did
NCT02611336 · Andrea M. Isidori
2016-07 – 2021-06 · Acromegaly Cardiomyopathy
What this study did
NCT02819440 · Vanderbilt University Medical Center
2016-07 – 2020-06 · Healthy, Obese
What this study did
NCT01862536 · VA Office of Research and Development
2013-10-01 – 2019-08-31 · Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01858558 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2013-09 – 2019-06-19 · Multiple Myeloma
What this study did
NCT02601989 · Göteborg University
2015-11 – 2019-01 · Diabetes Mellitus, Type 2
What this study did
NCT02450253 · St George's, University of London
2015-09 – 2018-01-25 · Dementia, Vascular
What this study did
NCT02801032 · Christina Kruuse
2016-11-29 – 2017-08-04 · Stroke, Lacunar, Cerebral Small Vessel Diseases
What this study did
NCT02194465 · Eli Lilly and Company
2014-08 – 2015-03 · Primary Hypertension
What this study did
NCT01697800 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2012-09 – 2014-07-14 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT01374217 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2012-04 – 2014-01 · Multiple Myeloma
What this study did
NCT01197469 · University of Dundee
2010-09 – 2012-09 · Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
What this study did
NCT00894413 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2007-05-08 – 2012-03 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT01160289 · Eli Lilly and Company
2010-10 – 2011-11 · Erectile Dysfunction
What this study did
NCT01200732 · Govind Ballabh Pant Hospital
2008-02 – 2010-07 · Eisenmenger Syndrome
What this study did
NCT00783094 · Eli Lilly and Company
2008-11 – 2010-04 · Benign Prostatic Hyperplasia
What this study did
NCT00538564 · Johns Hopkins University
2006-11 – 2009-08 · Sickle Cell Anemia, Priapism
What this study did
NCT00540124 · Eli Lilly and Company
2007-10 – 2008-06 · Benign Prostatic Hyperplasia
What this study did
NCT00386009 · Eli Lilly and Company
2006-10 – 2008-05 · Benign Prostatic Hyperplasia
What this study did
NCT00334477 · University of Pernambuco
— · Erectile Dysfunction
What this study did
NCT00157326 · Eli Lilly and Company
2005-09 – 2006-06 · Hypertension
What this study did
NCT00547625 · Eli Lilly and Company
2004-10 – 2005-07 · Prostatic Hyperplasia, Prostate
What this study did
NCT00174486 · Pfizer
2005-02 – 2005-06 · Impotence
What this study did
NCT00050609 · Eli Lilly and Company
2003-02 – 2003-09 · Gastroparesis
What this study did
NCT00707187 · University of Medicine and Dentistry of New Jersey
2001-07 – 2002-07 · Systemic Sclerosis
What this study did
Phase 1/2 (7)
Pulmonary Arterial Hypertension
NCT01484431 · Eli Lilly and Company
2012-07-17 – 2019-04-03 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT05030623 · Sadat City University
2021-08-01 – 2024-12-31 · Major Depressive Disorder
What this study did
NCT07206706 · Ain Shams University
2022-05-01 – 2022-12-28 · Management of Ureteric Stent Related LUTS and Pain
What this study did
NCT02058095 · Mayo Clinic
2014-03 – 2019-12 · Cardiomyopathy, Renal Impairment
What this study did
NCT01970176 · Mayo Clinic
2014-01-09 – 2019-09 · Cardiomyopathy, Renal Impairment
What this study did
NCT01544998 · Mayo Clinic
2012-02 – 2014-08 · Congestive Heart Failure
What this study did
NCT00274430 · University of Zurich
2003-07 – 2003-09 · High Altitude Pulmonary Edema
What this study did
Phase 1 (36)
Pulmonary Arterial Hypertension
NCT06553924 · Humanis Saglık Anonim Sirketi
2024-05-14 – 2024-08-08 · PAH
What this study did
NCT06553937 · Humanis Saglık Anonim Sirketi
2024-05-10 – 2024-07-31 · PAH
What this study did
NCT01244620 · Pfizer
2010-11 – 2010-12 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT07466030 · Assiut University
2026-03-01 – 2028-09-01 · BPH (Benign Prostatic Hyperplasia)
What this study did
NCT07117383 · Aspargo Labs, Inc
2026-01 – 2026-03 · Erectile Dysfunction
What this study did
NCT04762082 · Seattle Gummy Company
2025-05-01 – 2025-12-30 · Erectile Dysfunction
What this study did
NCT07447518 · Kafrelsheikh University
2022-09-22 – 2023-09-01 · Lower Urinary Tract Symptoms
What this study did
NCT05466695 · Assiut University
2022-08-01 – 2023-08-01 · Erectile Dysfunction and Neutrophil Lymphocyte Ratio
What this study did
NCT04757662 · Washington University School of Medicine
2021-05-14 – 2023-06-07 · Grade III Astrocytoma, Grade IV Astrocytoma, Astrocytoma, Grade IV, Astrocytoma, Grade III
What this study did
NCT02998736 · Ottawa Hospital Research Institute
2017-11-21 – 2022-10-01 · Abdominal Cancer
What this study did
NCT03238365 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2017-08-10 – 2022-09-08 · Lip, Oral Cavity and Pharynx, Larynx
What this study did
NCT04500860 · Kasr El Aini Hospital
2020-12-01 – 2022-07-01 · Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence
What this study did
NCT05095077 · University Hospital Bispebjerg and Frederiksberg
2021-08-01 – 2022-01-01 · Urinary Incontinence,Stress, Fecal Incontinence
What this study did
NCT04540744 · Janssen Research & Development, LLC
2021-04-30 – 2021-08-30 · Healthy
What this study did
NCT02544880 · Donald T. Weed, MD, FACS
2016-04-25 – 2021-06-08 · Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
What this study did
NCT03166787 · Cedars-Sinai Medical Center
2017-08-15 – 2020-10-15 · Smoking, Endothelial Dysfunction
What this study did
NCT04235270 · Janssen Research & Development, LLC
2020-01-17 – 2020-07-17 · Healthy
What this study did
NCT02653833 · Cedars-Sinai Medical Center
2017-11-01 – 2018-09-01 · Muscular Dystrophy
What this study did
NCT01342224 · Providence Health & Services
2011-01 – 2018-04 · Locally Advanced Pancreatic Adenocarcinoma
What this study did
NCT01903083 · Providence Health & Services
2013-07 – 2017-12 · Locally Advanced Malignant Neoplasm
What this study did
NCT02688387 · GlaxoSmithKline
2016-03-18 – 2017-08-04 · Hypertension, Pulmonary
What this study did
NCT02839122 · Yuyu Pharma, Inc.
2016-05 – 2016-09-23 · Benign Prostate Hyperplasia
What this study did
NCT02352311 · Dongkook Pharmaceutical Co., Ltd.
2015-01 – 2015-06 · Benign Prostate Hyperplasia, Healthy
What this study did
NCT02300259 · Eli Lilly and Company
2014-11 – 2015-04 · Healthy Volunteers
What this study did
NCT02247505 · Chong Kun Dang Pharmaceutical
2014-09 – 2014-12 · Healty Male Volunteers
What this study did
NCT02247518 · Chong Kun Dang Pharmaceutical
2014-09 – 2014-12 · Healthy
What this study did
NCT02239484 · Hanmi Pharmaceutical Company Limited
2014-03 – 2014-09 · Erectile Dysfunction, Benign Prostatic Hyperplasia
What this study did
NCT01291069 · University of Utah
2011-09 – 2014-02 · Single Ventricle
What this study did
NCT01942551 · Dongkook Pharmaceutical Co., Ltd.
2013-09 – 2013-12 · Benign Prostate Hyperplasia
What this study did
NCT01359670 · Cedars-Sinai Medical Center
2011-05 – 2013-05 · Duchenne Muscular Dystrophy
What this study did
NCT01580501 · Cedars-Sinai Medical Center
2012-03 – 2013-03 · Duchenne Muscular Dystrophy
What this study did
NCT01238224 · Vastra Gotaland Region
2009-11 – 2011-11 · Type 2 Diabetes
What this study did
NCT01183650 · Eli Lilly and Company
2010-07 – 2011-04 · Benign Prostatic Hyperplasia
What this study did
NCT02253862 · Boehringer Ingelheim
2005-12 – 2006-03 · Healthy
What this study did
Phase 4 (52)
Pulmonary Arterial Hypertension
NCT03236818 · Amsterdam UMC, location VUmc
2013-05 – 2017-09 · Pulmonary Arterial Hypertension
What this study did
NCT01042158 · Johns Hopkins University
2010-01 – 2014-11 · Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases, Connective Tissue Disease, Pulmonary Hypertension
What this study did
NCT01302444 · Rhode Island Hospital
2011-03 – 2012-03 · Pulmonary Arterial Hypertension
What this study did
NCT00705588 · Rabin Medical Center
2008-08 – 2010-01 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT07654413 · Beni-Suef University
2026-06-08 – 2027-12 · Acute Urinary Retention, Benign Prostatic Hyperplasia, Benign Prostatic Obstruction
What this study did
NCT07753720 · Al-Azhar University
2026-08-13 – 2027-06-30 · Erectile Dysfunction, Tadalafil
What this study did
NCT07391579 · Mansoura University
2025-12-01 – 2027-06 · Erectile Dysfunctions
What this study did
NCT05051436 · Philip Kern
2021-12-13 – 2027-01 · Pre-diabetes, Obesity
What this study did
NCT07416968 · Mansoura University
2025-09-01 – 2026-12 · Overactive Bladder (OAB), Overactive Bladder Syndrome
What this study did
NCT07499804 · Beni-Suef University
2023-10-01 – 2026-04-30 · IVF, Infertility, Female
What this study did
NCT07715448 · Beni-Suef University
est. completion 2026-01-01 · Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms, Erectile Dysfunction
What this study did
NCT07602608 · Benha University
2025-04-15 – 2025-12-16 · Erectile Dysfunction
What this study did
NCT06947265 · Fayoum University Hospital
2024-01-14 – 2025-02-01 · Erectile Dysfunctions
What this study did
NCT06809205 · Fayoum University Hospital
2023-04-20 – 2024-08-30 · BPH With Other Lower Urinary Tract Symptoms
What this study did
NCT03177746 · Neutec Ar-Ge San ve Tic A.Ş
2022-12-31 – 2023-10-14 · Premature Ejaculation, Erectile Dysfunction, Safety Issues
What this study did
NCT05537272 · University Hospital of Split
2022-09-01 – 2023-09-01 · Lower Urinary Tract Symptoms, Voiding Disorders, Pain, Quality of Life
What this study did
NCT05818670 · Mansoura University
2020-11-11 – 2022-09-17 · BPH
What this study did
NCT05494567 · Mansoura University
2021-11-08 – 2022-08 · Benign Prostatic Hyperplasia, Overactive Bladder
What this study did
NCT03229889 · University of California, Irvine
2017-06-07 – 2022-03-24 · Nephrolithiasis
What this study did
NCT04641507 · Beni-Suef University
2020-01-01 – 2022-03-05 · Lower Ureteric Stones
What this study did
NCT05446493 · Aswan University
2019-04-01 – 2022-01-05 · Erectile Dysfunction, Erectile Dysfunction With Diabetes Mellitus
What this study did
NCT02252367 · University of Florence
2015-12 – 2020-06 · Prostatic Hyperplasia, Lower Urinary Tract Symptoms
What this study did
NCT04946162 · Santa Barbara Cottage Hospital
2020-04-20 – 2020-04-20 · COVID, Sars-CoV2, ARDS, Human
What this study did
NCT01803828 · University of Roma La Sapienza
2014-05 – 2019-07 · Diabetic Cardiomyopathy, Diabetes Mellitus Type 2
What this study did
NCT02225548 · University of South Florida
2014-09 – 2019-01 · Parkinson's Disease, Erectile Dysfunction
What this study did
NCT03309592 · Ochsner Health System
2017-10-12 – 2018-11-01 · Portopulmonary Hypertension, Pulmonary Hypertension, Cirrhosis, Liver
What this study did
NCT02943356 · The Catholic University of Korea
2016-07 – 2017-07 · Erectile Dysfunction, Andropause
What this study did
NCT02224846 · Eli Lilly and Company
2014-10 – 2017-05 · Erectile Dysfunction
What this study did
NCT01275339 · Washington University School of Medicine
2012-12 – 2017-04-14 · Aortic Stenosis, LV Remodeling, Hypertrophy
What this study did
NCT02431754 · Eli Lilly and Company
2015-04 – 2016-02 · Benign Prostatic Hyperplasia
What this study did
NCT02595684 · University of Guadalajara
2015-08 – 2015-11 · Obesity
What this study did
NCT02554045 · University of Roma La Sapienza
2015-01 – 2015-09 · Obesity, Sexual Dysfunction
What this study did
NCT01067391 · University of Manitoba
2009-10 – 2015-07 · Hypotension, Spinal Cord Injury
What this study did
NCT01305252 · Stanford University
2010-07 – 2014-09 · Hypertension, Pulmonary
What this study did
NCT01326117 · Mark Feinglos
2011-04 – 2013-12 · Gastroparesis, Diabetic Gastroparesis, Nausea, Vomiting
What this study did
NCT01070511 · Cedars-Sinai Medical Center
2010-01 – 2012-12 · Becker Muscular Dystrophy
What this study did
NCT01026818 · Eli Lilly and Company
2009-11 – 2012-10 · Erectile Dysfunction
What this study did
NCT01364701 · Rambam Health Care Campus
2011-06 – 2012-07 · Erectile Dysfunction
What this study did
NCT01352507 · Eli Lilly and Company
2011-06 – 2012-07 · Erectile Dysfunction
What this study did
NCT01272388 · Washington University School of Medicine
2011-01 – 2012-04 · Aortic Stenosis
What this study did
NCT01130532 · Eli Lilly and Company
2010-08 – 2012-01 · Erectile Dysfunction
What this study did
NCT01122264 · Eli Lilly and Company
2010-05 – 2011-06 · Erectile Dysfunction
What this study did
NCT00833638 · Eli Lilly and Company
2009-02 – 2009-06 · Erectile Dysfunction
What this study did
NCT00333281 · Eli Lilly and Company
2005-06 – 2006-08 · Erectile Dysfunction
What this study did
NCT00382135 · Eli Lilly and Company
2003-11 – 2005-12 · Erectile Dysfunction
What this study did
NCT00422578 · Eli Lilly and Company
2004-10 – 2005-09 · Impotence, Erectile Dysfunction
What this study did
NCT00547352 · Eli Lilly and Company
2004-06 – 2005-06 · Impotence
What this study did
NCT00547092 · Eli Lilly and Company
2003-10 – 2004-11 · Impotence
What this study did
Early phase / not applicable (27)
Pulmonary Arterial Hypertension
NCT06968962 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-05-14 – 2028-12 · Pulmonary Arterial Hypertension (PAH)
What this study did
Other / comorbidity
NCT07722884 · Ain Shams University
2026-07-01 – 2027-01-01 · Safety, Efficacy, Tamsulosin, Monotherapy, Tadalafil, Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
What this study did
NCT06442020 · Regina Elena Cancer Institute
2023-09-15 – 2026-09-15 · Erectile Dysfunction
What this study did
NCT07562282 · Ain Shams University
2025-12-01 – 2026-07-10 · Kidney Stone, Ureteric Stone
What this study did
NCT07690566 · Deraya University
2025-09-01 – 2025-12-20 · Diabetic Foot, Wound Healing Delayed, Diabete Mellitus, Amputation
What this study did
NCT07312955 · Ain Shams University
2025-05-15 – 2025-11-15 · Overactive Bladder
What this study did
NCT06350773 · Beni-Suef University
2023-03-10 – 2025-10-25 · Group 2 Pulmonary Hypertension, CpcPH
What this study did
NCT06962462 · South Valley University
2025-05-05 – 2025-08-30 · Erectile Dysfunction Associated With Type 2 Diabetes Mellitus
What this study did
NCT06213077 · RHA Investments Ltd
2023-12-12 – 2024-05-30 · Erectile Dysfunction
What this study did
NCT05823506 · Saint Petersburg State University, Russia
2023-02-01 – 2024-02-01 · Erectile Dysfunction
What this study did
NCT06184334 · Elsayed Abdelhalim Elsayed
2022-09-14 – 2023-12-01 · Overactive Bladder
What this study did
NCT05146674 · Mansoura University
2022-01-01 – 2023-01-01 · Lower Urinary Tract Symptoms
What this study did
NCT03642366 · Institute for the Study of Urological Diseases, Greece
2018-08-27 – 2022-12 · Erectile Dysfunction
What this study did
NCT05789732 · Benha University
2022-03-30 – 2022-08-30 · Lower Ureteric Stones, Medical Expulsive Therapy, Tadalafil, Silodosin
What this study did
NCT05109377 · Ankara Training and Research Hospital
2021-06-24 – 2021-12-15 · Erectile Dysfunction
What this study did
NCT03641846 · Institute for the Study of Urological Diseases, Greece
2018-08-28 – 2021-04-16 · Erectile Dysfunction, Low Intensity Shockwave Therapy
What this study did
NCT04623840 · Cairo University
2020-10-12 – 2021-03-30 · Erectile Dysfunction
What this study did
NCT03566914 · Institute of Liver and Biliary Sciences, India
2018-06-30 – 2019-12-28 · Cirrhosis
What this study did
NCT03834610 · Aswan University Hospital
2017-10-01 – 2018-10-01 · Erectile Dysfunction
What this study did
NCT01661595 · The University of Texas Medical Branch, Galveston
2012-11 – 2015-06 · Fatigue
What this study did
NCT00843635 · Donald T. Weed
2008-09 – 2015-04 · Head and Neck Cancer
What this study did
NCT01743911 · University of Campinas, Brazil
2010-09 – 2012-08 · Hypertension
What this study did
NCT01060969 · Sheba Medical Center
2006-01 – 2010-08 · Pulmonary Edema, Cerebral Edema
What this study did
NCT00822354 · Northwestern University
2008-09 – 2010-04 · Raynaud
What this study did
NCT00506701 · Herlev Hospital
2008-02 – 2010-02 · Chronic Obstructive Lung Disease
What this study did
NCT00463957 · University of Cambridge
started 2006-08 · Erectile Dysfunction
What this study did
NCT00750308 · Vanderbilt University
2006-12 – 2009-05 · Metabolic Syndrome
What this study did
Used as active comparator (16)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (5)
Pulmonary Arterial Hypertension
NCT03904693 · Actelion
2019-07-29 – 2024-09-27 · Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
What this study did
Other / comorbidity
NCT05052879 · EMS
2024-07 – 2026-08 · Erectile Dysfunction, Premature Ejaculation
What this study did
NCT04947631 · Dongkook Pharmaceutical Co., Ltd.
2021-07-27 – 2023-06-12 · Benign Prostatic Hyperplasia
What this study did
NCT03246880 · Chong Kun Dang Pharmaceutical
2015-09 – 2016-05 · Benign Prostatic Hyperplasia
What this study did
NCT00668109 · Bayer
2003-12 – 2004-06 · Erectile Dysfunction
What this study did
Phase 2 (3)
Pulmonary Arterial Hypertension
NCT04483115 · Vigonvita Life Sciences
2020-11-16 – 2022-06-29 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT05558007 · Biozeus Biopharmaceutical S.A.
2023-11-22 – 2025-01-31 · Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction, Prostate Cancer, Radical Prostatectomy
What this study did
NCT01423370 · Yuhan Corporation
2011-11 – 2013-03 · Erectile Dysfunction
What this study did
Phase 1 (2)
Other / comorbidity
NCT03240939 · Yuyu Pharma, Inc.
2017-03-27 – 2017-10-10 · Benign Prostatic Hyperplasia
What this study did
NCT01401543 · Eli Lilly and Company
2011-07 – 2011-09 · Erectile Dysfunction
What this study did
Phase 4 (4)
Pulmonary Arterial Hypertension
NCT02891850 · Bayer
2017-01-11 – 2020-03-03 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT07642505 · Beni-Suef University
2026-06-08 – 2026-12 · Erectile Dysfunction
What this study did
NCT07563647 · Kafrelsheikh University
2025-05-05 – 2026-03-17 · Erectile Dysfunction, Left Ventricular Diastolic Dysfunction, Metabolic Syndrome
What this study did
NCT00663130 · Bayer
2004-04 – 2004-07 · Erectile Dysfunction
What this study did
Early phase / not applicable (2)
Other / comorbidity
NCT05199727 · Menoufia University
2021-09-01 – 2022-05 · Erectile Dysfunction
What this study did
NCT04446598 · Adrian Gaspar
2017-03-13 – 2018-12-31 · Chronic Prostatitis With Chronic Pelvic Pain Syndrome, Prostatodynia
What this study did
Appears in other studies (10)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (4)
Pulmonary Arterial Hypertension
NCT07245680 · Assistance Publique - Hôpitaux de Paris
2026-04-28 – 2029-02-14 · Pulmonary Arterial Hypertension (PAH), Comorbidities, Cardiovascular Disease (CVD)
What this study did
NCT02558231 · Actelion
2016-05-01 – 2020-04-20 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT06717711 · Regina Elena Cancer Institute
2023-09-15 – 2028-02-28 · Prostate Carcinoma, Erectile Function, Genito Urinary Cancer
What this study did
NCT04361305 · Yan-Ping Huang
2020-06-03 – 2021-04-01 · Premature Ejaculation, Erectile Dysfunction
What this study did
Phase 4 (2)
Pulmonary Arterial Hypertension
NCT00617305 · Gilead Sciences
2008-04 – 2011-07 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT07636161 · University of Miami
2026-10 – 2027-09 · Type 2 Diabetes, Type 2 Diabetes (T2DM)
What this study did
Early phase / not applicable (4)
Other / comorbidity
NCT07879105 · Biruni University
2026-02-04 – 2026-05-25 · Premature Ejaculation
What this study did
NCT07844213 · China National Center for Cardiovascular Diseases
2022-08-25 – 2025-08-31 · Congenital Heart Disease, Pulmonary Hypertension
What this study did
NCT06543628 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2024-08-11 – 2025-03-03 · Erectile Dysfunction
What this study did
NCT05043896 · Dr. Soetomo General Hospital
2019-12-10 – 2020-06-30 · Erectile Dysfunction
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Pulmonary Arterial Hypertension: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tadalafil (Adcirca): this drugApprovedSmall moleculePDE5Weak signal
NCT01824290: 6-minute walk distance change from baseline at Week 24: LS mean 60.48 m (SE 20.41) tadalafil vs 36.60 m (SE 20.78) placebo; placebo-adjusted mean difference 23.88 m (SD 29.11) missed
NCT00549302: 6-minute walk distance (6MWD), PHIRST-2 enrollment vs PHIRST-2 completion: tadalafil 20mg 406±67m (n=52) -> 415±80m (n=51); tadalafil 40mg 413±81m (n=59) -> 410±78m (n=59) - improvements from the 16-week PHIRST study were maintained through 52 additional weeks.
Ambrisentan (Letairis)ApprovedSmall moleculeEndothelin A receptorReliable signal
NCT01178073: Time to first adjudicated clinical failure: combination therapy vs pooled monotherapy, hazard ratio 0.502 (95% CI 0.348-0.724, p=0.0002) - 50% risk reduction
NCT00091598: 6-minute walk distance change from baseline to Week 12 (ARIES-1), placebo-corrected: +31 m with ambrisentan 5 mg (P=0.008); +51 m with ambrisentan 10 mg (P<0.001).
Bosentan (Tracleer)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Partial signal
NCT00091715: Co-primary endpoints at month 6: pulmonary vascular resistance treatment effect -22.6% vs placebo (p<0.0001); 6-min walk distance (exercise capacity) treatment effect +19.1 m vs placebo (p=0.0758, not significant)
NCT00319267: AUCt for bosentan: geometric mean ratio of paediatric vs. historical-adult exposure = 0.54 (90% CI 0.37-0.78) — children had lower exposure than adults.
Epoprostenol (Flolan)
ApprovedUS marketing discontinued
Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Macitentan (Opsumit)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Partial signal
NCT00660179: Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)): ACT-064992 3 mg — Kaplan-Meier estimate at Month 6: 89.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 81.6 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 72.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 65.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 61.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 55 percentage of participants-Kaplan Meier | ACT-064992 10 mg — Kaplan-Meier estimate at Month 6: 92.7 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 85.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 79.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 74.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 70 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 63.2 percentage of participants-Kaplan Meier vs Placebo — Kaplan-Meier estimate at Month 6: 80.1 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 71.4 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 61.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 57.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 50.2 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 47 percentage of participants-Kaplan Meier
Riociguat (Adempas)ApprovedSmall moleculeSoluble guanylate cyclaseReliable signal
NCT00810693: 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12 (Baseline and week 12): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT 29.6 Meters (Standard Deviation 65.8) | Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT 31.1 Meters (Standard Deviation 79.3) vs Placebo -5.6 Meters (Standard Deviation 85.5)
Sildenafil (Revatio)ApprovedSmall moleculePDE5Partial signal
NCT00644605: The mean placebo-corrected treatment effects for 6-minute walk distance were 45 m (+13.0 percent), 46 m (+13.3 percent) and 50 m (+14.7 percent) for sildenafil doses of 20, 40 and 80 mg respectively; all comparisons achieved statistical significance (P<0.001).
Sotatercept (Winrevair)ApprovedProtein / enzyme therapeuticActivin receptor type IIA (ActRIIA)Reliable signal
NCT04576988: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24): Sotatercept Plus Background PAH Therapy (DBPC Period) 34.4 meters (range 32.5 to 35.5) vs Placebo Plus Background PAH Therapy (DBPC Period) 1 meters (range -1 to 5)
NCT04896008: First death, lung transplantation or PAH-worsening hospitalization: sotatercept 17.4% (15/86) vs placebo 54.7% (47/86), HR 0.24 (95% CI 0.13 to 0.43), P<0.001; trial stopped early for efficacy (ZENITH, NEJM 2025).
Treprostinil (Orenitram)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT00325403: Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49)
Treprostinil (Remodulin)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso DPI)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT00147199: Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5)
Treprostinil (Yutrepia, Liquidia)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Weak signalFeatured results are safety only in this race
AR1001
Phase 3(overall)
Small moleculePDE5
Partial signal(overall)
No reviewed efficacy summary in this indication
Extended-Release Tacrolimus (VI-0106)Phase 3Small moleculeCalcineurinnot yet gradedNo reviewed efficacy summary in this indication
Imatinib Mesylate Prodrug (IkT-001Pro)Phase 3Small moleculePDGFR (imatinib-class)not yet gradedNo reviewed efficacy summary in this indication
RalinepagPhase 3Small moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT03626688: Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001.
SeralutinibPhase 3Small moleculePDGFR/CSF1R/KIT (multi-kinase)Partial signal
NCT05934526: Change in 6MWD at Week 24 (PROSERA): seralutinib +28.2m vs placebo +13.5m; Hodges-Lehmann placebo-adjusted treatment effect +13.3m (p=0.0320), which did not meet the prespecified α=0.025 significance threshold missed
Treprostinil (L606)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Udenafil (Zydena)Phase 2/3Small moleculePDE5Weak signalNo reviewed efficacy summary in this indication
APL-9796Phase 2Monoclonal antibodyZIP12 (zinc transporter)not yet gradedNo reviewed efficacy summary in this indication
ROC-101Phase 2Small moleculeRho-associated kinase (ROCK, pan)not yet gradedNo reviewed efficacy summary in this indication
RTN-001
Phase 2(overall)
Small moleculePDE5
not yet graded(overall)
No reviewed efficacy summary in this indication
VasigrobartPhase 2Monoclonal antibodyPDGF-Bnot yet gradedNo reviewed efficacy summary in this indication
ZamicastatPhase 2Small moleculeDBHWeak signalNo reviewed efficacy summary in this indication
HS235Phase 1/2PeptideActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
F230
—(overall)
Small moleculeEndothelin A receptornot yet gradedNo reviewed efficacy summary in this indication
GSK6792070
—(overall)
UndisclosedActivin signallingnot yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)Weak signal
NCT01469169: Change in Pulmonary vascular resistance (PVR) from baseline to week 12: improved by -124 dyn·sec·cm-5 (95% CI, -177 to -72); 6-minute walking distance increased by 36.0 m (95% CI, 14.9 to 57.1)
PF-07868489DiscontinuedProtein / enzyme therapeuticBone morphogenetic protein 9 (BMP9)Partial signalNo reviewed efficacy summary in this indication

Upcoming events

(16 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Adcirca (Tadalafil) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
November 2026 (2)
Phase 2Duchenne Muscular Dystrophy, Duchenne Disease, Muscular Dystrophy, Muscular Dystrophy in Children, Vasodilation, Exercise, DMDRecruiting
Est. primary completion 2026-11 · NCT06290713 · CT.gov ↗
What to watch
Phase 3Fontan PalliationRecruiting
Est. primary completion 2026-11 · NCT05206955 · CT.gov ↗
What to watch
December 2026 (1)
Phase 4Erectile DysfunctionsRecruiting
Est. primary completion 2026-12 · NCT07391579 · CT.gov ↗
What to watch
2027 (7)
January 2027 (3)
Phase 4Pre-diabetes, ObesityRecruiting
Est. primary completion 2027-01 · NCT05051436 · CT.gov ↗
What to watch
Early phase / not applicableSafety, Efficacy, Tamsulosin, Monotherapy, Tadalafil, Lower Urinary Tract Symptoms, Benign Prostatic HyperplasiaRecruiting
Est. primary completion 2027-01-01 · NCT07722884 · CT.gov ↗
What to watch
Phase 3Hypertension, PulmonaryRecruiting
Est. primary completion 2027-01-31 · NCT05179876 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2Mild Cognitive Impairment (MCI)Not yet recruiting
Est. primary completion 2027-02-20 · NCT07882901 · CT.gov ↗
What to watch
June 2027 (1)
Phase 4Erectile Dysfunction, TadalafilRecruiting
Est. primary completion 2027-06-30 · NCT07753720 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3Pulmonary Hypertension, Chronic Obstructive Pulmonary DiseaseRecruiting
Est. primary completion 2027-10 · NCT05844462 · CT.gov ↗
What to watch
November 2027 (1)
Phase 4Acute Urinary Retention, Benign Prostatic Hyperplasia, Benign Prostatic ObstructionRecruiting
Est. primary completion 2027-11 · NCT07654413 · CT.gov ↗
What to watch
2028 (5)
March 2028 (1)
Phase 1BPH (Benign Prostatic Hyperplasia)Not yet recruiting
Est. primary completion 2028-03-01 · NCT07466030 · CT.gov ↗
What to watch
May 2028 (1)
Early phase / not applicablePulmonary Arterial HypertensionRecruiting
Est. primary completion 2028-05 · NCT06968962 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Alzheimer DiseaseNot yet recruiting
Est. primary completion 2028-08 · NCT07172815 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Erectile DysfunctionNot yet recruiting
Est. primary completion 2028-09 · NCT07537855 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Erectile Dysfunction Following Radical Prostatectomy, Prostate Cancer, Urinary Incontinence Following Surgical ProcedureRecruiting
Est. primary completion 2028-12-01 · NCT07576335 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Phase 2Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension, DyspneaRecruiting
Est. primary completion 2029-03-01 · NCT05937854 · CT.gov ↗
What to watch

See the full readout calendar ↗